

**AMENDMENT**

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

**IN THE CLAIMS:**

Please add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

--65. (New) A pharmaceutical or veterinary paste formulation comprising:

(a) an effective amount of a Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one characterized by the following parameters:

cristalline system	Trigonal
space group	R-3
description	hexagonal
<b>unit-cell dimensions</b>	
a (Å)	18.183
b (Å)	18.183
c (Å)	26.950
$\alpha$ (°)	90
$\beta$ (°)	90
$\gamma$ (°)	120
unit-cell volume (Å <sup>3</sup> )	7716.5
number of molecules per unit-cell Z	18
Temperature of measurement (°K)	293
calculated specific gravity	1.303
weight absorption coefficient (cm <sup>-1</sup> )	2.11

(b) a fumed silica;

(c) a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica; and

(d) a carrier.

66. (New) A pharmaceutical or veterinary paste formulation according to claim 65, wherein the Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one is further characterized by the following X-ray diffraction data calculated from crystalline structure

d(Angs)	Intensity
13,596	w
10,238	w
9,092	s
8,983	m
7,558	vw
6,798	vw
6,39	m
6,39	vw
6,194	vw
5,812	m
5,812	w
5,444	w
5,444	vw
5,249	s
5,119	s
5,1	vw
4,546	vw
4,532	s
4,532	s
4,492	m
4,461	m
4,448	w
4,311	vw
4,311	vw
4,155	s
4,155	m
4,056	vw
4,056	vw
4,027	vw
4,027	vw
3,995	m
3,995	w
3,895	w
3,74	vw
3,665	vw
3,665	vw
3,581	m
3,489	vw
3,489	vw
3,459	vw
3,436	vw

d(Angs)	Intensity
3,209	vw
3,195	w
3,195	vw
3,184	m
3,184	vw
3,179	vw
3,128	vw
3,067	vw
3,031	vw
3,001	vw
3,001	vw
2,994	vw
2,958	vw
2,958	vw
2,932	vw
2,906	vw
2,906	vw
2,888	vw
2,853	vw
2,844	vw
2,813	vw
2,768	vw
2,753	vw
2,729	vw
2,729	vw
2,722	vw
2,722	vw
2,719	vw
2,667	w
2,667	vw
2,634	vw
2,624	vw
2,608	vw
2,522	vw
2,519	vw
2,519	vw
2,512	vw
2,504	vw
2,504	vw
2,501	vw
2,464	vw

3,436	vw
3,413	w
3,413	vw
3,399	vw
3,393	m
3,393	vw
3,233	vw
3,209	w

2,464	vw
2,455	vw
2,438	vw
2,428	vw
2,428	vw
2,417	vw
2,364	vw
2,339	vw
2,301	vw

67. (New) The pharmaceutical or veterinary paste formulation of claim 65 additionally comprising:

- (d) an absorbant;
- (e) a colorant; and
- (f) a carrier selected from the group consisting of a triacetin, a

monoglyceride, a diglyceride, and a triglyceride.

68. (New) The pharmaceutical or veterinary paste formulation according to claim 67, wherein the viscosity modifier is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene sorbiton monoleate, and poloxamers; the absorbent is selected from the group consisting of magnesium carbonate, calcium carbonate, starch, and cellulose and its derivatives; and the colorant is selected from the group consisting of titanium dioxide, dye and lake.

69. (New) The pharmaceutical or veterinary paste formulation according to claim 65, which, based upon total weight of formulation, comprises:

- (a) about 0.01 to about 50% of the Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one;
- (b) about 0.02% to about 20% fumed silica;
- (c) about 0.01% to about 20% of a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica;
- (d) 0% to about 30% of an absorbent;
- (e) 0% to about 20% of a colorant; and
- (f) a carrier

70. (New) The pharmaceutical or veterinary paste formulation according to claim 67, which based upon total weight of the formulation, comprises:

- (a) about 0.01 to about 50% of the Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one;
- (b) about 1% to about 6.5% fumed silica;
- (c) about 0.05% to about 5% of a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica;
- (d) about 1% to about 10% of an absorbent;
- (e) 0.01% to about 10% of a colorant; and
- (f) a carrier.

71. (New). The pharmaceutical or veterinary paste formulation according to claim 67, wherein the colorant is  $\text{TiO}_2$ , the viscosity modifier is PEG 300, the carrier is triacetin, and the absorbent is magnesium carbonate.

72. (New) The pharmaceutical or veterinary paste formulation according to claim 65, further comprising an absorbent.

73. (New) The pharmaceutical or veterinary paste formulation according to claim 65, further comprising a compound selected from the group consisting of a colorant, a stabilizer, a surfactant and a preservative. --

Please cancel claims 50-64, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.